Reliable and traceable starting materials, such as high-quality human induced pluripotent stem cell (hiPSC) lines, are essential for enabling reproducible PSC-derived cell therapy development. However, many research-grade materials are generated under donor, consent, or process constraints that prevent rederivation under GMP conditions, which limits their suitability for clinical translation.

To address these challenges, LineaBio has introduced the GMP-grade hiPSC lines, Linea 1 and Linea 2, produced under defined, quality-controlled processes. In partnership with STEMCELL Technologies, matched research-grade equivalents are derived from the same source material and qualified to meet or exceed ISSCR standards. Selecting matched starting materials enables smoother advancement through development stages and lowers the likelihood of requiring process redesign at later phases.

Watch this webinar to learn how LineaBio’s GMP-grade manufacturing framework, combined with STEMCELL’s rigorous quality control for matched research-grade cell lines, can support your PSC-derived cell therapy development. You may also sign up to be notified when these products launch.